Pawel Baranczewski

Pawel Baranczewski

Auto-generated profile, based on publicly available information

Pawel Baranczewski

Department of Pharmacy, SciLifeLab Drug Discovery and Development Uppsala University Uppsala Sweden

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2021 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
JBJurgen Brem
Jurgen Brem
TPTharindi Panduwawala
Tharindi Panduwawala
JHJon Ulf Hansen
Jon Ulf Hansen
JHJoanne Hewitt
Joanne Hewitt
ELEdgars Liepins
Edgars Liepins
CSChristopher J. Schofield
Christopher J. Schofield

9 August 2024 in Science Advances
Verified
Journal Article
Open access
ADAlejandro Díaz-Holguín
Alejandro Díaz-Holguín
MSMarcus Saarinen
Marcus Saarinen
DVDuc Duy Vo
Duc Duy Vo
ASAndrea Sturchio
Andrea Sturchio
NBNiclas Branzell
Niclas Branzell
Per SvenningssonPer Svenningsson
Per Svenningsson
Artificial intelligence is revolutionizing protein structure prediction, providing unprecedented opportunities for drug design. To assess the potential impact on ligand discovery, we compared virtual screens using protein structures generated by the AlphaFold machine learning method and traditional homology modeling. More than 16 million compounds were docked to models of the trace amine–associated receptor 1 (TAAR1), a G protein–coupled receptor of unknown structure and target for treating neuropsychiatric disorders. Sets of 30 and 32 highly ranked compounds from the AlphaFold and homology model screens, respectively, were experimentally evaluated. Of these, 25 were TAAR1 agonists with potencies ranging from 12 to 0.03 μM. The AlphaFold screen yielded a more than twofold higher hit rate (60%) than the homology model and discovered the most potent agonists. A TAAR1 agonist with a promising selectivity profile and drug-like properties showed physiological and antipsychotic-like effects in wild-type but not in TAAR1 knockout mice. These results demonstrate that AlphaFold structures can accelerate drug discovery.

5 April 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DHDouglas L. Huseby
Douglas L. Huseby
SCSha Cao
Sha Cao
EZEdouard Zamaratski
Edouard Zamaratski
SSSanjeewani Sooriyaarachchi
Sanjeewani Sooriyaarachchi
SAShabbir Ahmad
Shabbir Ahmad
AKAnders Karlén
Anders Karlén
Here, we describe the identification of an antibiotic class acting via LpxH, a clinically unexploited target in lipopolysaccharide synthesis. The lipopolysaccharide synthesis pathway is essential in most Gram-negative bacteria and there is no analogous pathway in humans. Based on a series of phenotypic screens, we identified a hit targeting this pathway that had activity on efflux-defective strains of Escherichia coli . We recognized common structural elements between this hit and a previously published inhibitor, also with activity against efflux-deficient bacteria. With the help of X-ray structures, this information was used to design inhibitors with activity on efflux-proficient, wild-type strains. Optimization of properties such as solubility, metabolic stability and serum protein binding resulted in compounds having potent in vivo efficacy against bloodstream infections caused by the critical Gram-negative pathogens E. coli and Klebsiella pneumoniae . Other favorable properties of the series include a lack of pre-existing resistance in clinical isolates, and no loss of activity against strains expressing extended-spectrum-β-lactamase, metallo-β-lactamase, or carbapenemase-resistance genes. Further development of this class of antibiotics could make an important contribution to the ongoing struggle against antibiotic resistance.

1 January 1998 in Chromosome Research
Verified
Journal Article
Closed access
PDF file
NBN. D. Belyaev
N. D. Belyaev
Andreas HoubenAndreas Houben
Andreas Houben
PBP. Baranczewski
P. Baranczewski
Ingo SchubertIngo Schubert
Ingo Schubert

1 June 2007 in Toxicology
Verified
Journal Article
Closed access
JDJulie Desrivot
Julie Desrivot
PEPer-Olof Edlund
Per-Olof Edlund
RSRichard Svensson
Richard Svensson
PBPawel Baranczewski
Pawel Baranczewski
AFAlain Robert Fournet
Alain Robert Fournet
CHChristine Herrenknecht
Christine Herrenknecht

13 November 2023 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
HNHedvig Nordeng
Hedvig Nordeng
CWChristine Wegler
Christine Wegler
ALAnnika Lindqvist
Annika Lindqvist
EMErik Melander
Erik Melander
MMMikaela Magnusson
Mikaela Magnusson
OSOlav Spigset
Olav Spigset
Data on drug transfer into human breast milk are sparse. This study aimed to quantify concentrations of cetirizine and levocetirizine in breast milk and to estimate drug exposure to infants. Breastfeeding women at least 8 weeks postpartum and using cetirizine or its pure (R)‐enantiomer levocetirizine were eligible to participate. Breast milk samples were collected at six predefined times during a dose interval (0, 2, 4, 8, 12 and 24 h after drug intake) at steady state. Infant drug exposure was estimated by calculating the absolute infant dose (AID) and the weight‐adjusted relative infant dose (RID). In total, 32 women were eligible for final inclusion, 31 women using cetirizine and one woman using levocetirizine. Means of the individual maximum and average cetirizine milk concentrations were 41.0 and 16.8 μg/L, respectively. Maximum concentrations occurred on average 2.4 h after intake, and the mean half‐life in milk was 7.0 h. Estimated AID and RID for cetirizine in a day were 2.5 μg/kg and 1.9%, respectively. The corresponding values for levocetirizine were 1.1 μg/kg and 1.9%. No severe adverse events were reported. Our findings demonstrate that the transfer of cetirizine and levocetirizine into breast milk is low and compatible with breastfeeding.